Articles dans des revues avec comité de lecture (167)
44.
Nielsen, T. O., Poulsen, S. S., Journé, F., Ghanem, G. E., & Sorensen, B. S. (2014). HER4 and its cytoplasmic isoforms are associated with progression-free survival of malignant melanoma. Melanoma research, 24(1), 88-91. doi:10.1097/CMR.000000000000004045.
Krayem, M., Journé, F., Wiedig, M., Morandini, R., Sales, F., Awada, A., & Ghanem, G. E. (2014). Prominent role of cyclic adenosine monophosphate signalling pathway in the sensitivity of (WT)BRAF/(WT)NRAS melanoma cells to vemurafenib. European journal of cancer. doi:10.1016/j.ejca.2014.01.02146.
Denecker, G., Vandamme, N., Akay, Ö. O., Taminau, J., Gheldof, A., De Craene, B., Berx, G., Lemeire, K., Haigh, J. J., Koludrovic, D., Davidson, I., Van Gele, M., Brochez, L., Udupi, G. M., Gallagher, W. W., Rafferty, M., Balint, B., Ghanem, G. E., Huylebroeck, D., van den Oord, J., Larue, L., & Marine, J.-C. (2014). Identification of a ZEB2-MITF-ZEB1 transcriptional network that controls melanogenesis and melanoma progression. Cell death and differentiation, 21(8), 1250-1261. doi:10.1038/cdd.2014.4447.
Kamagaju, L., Bizuru, E., Minani, V., Morandini, R., Stévigny, C., Ghanem, G. E., & Duez, P. (2013). An ethnobotanical survey of medicinal plants used in Rwanda for voluntary depigmentation. Journal of ethnopharmacology, 150(2), 708-717. doi:10.1016/j.jep.2013.09.03148.
Aftimos, P., Wiedig, M., Langouo Fontsa, M., Awada, A., Ghanem, G. E., & Journé, F. (2013). Sequential use of protein kinase inhibitors potentiates their toxicity to melanoma cells: a rationale to combine targeted drugs based on protein expression inhibition profiles. International journal of oncology, 43(3), 919-926. doi:10.3892/ijo.2013.200849.
Kindt, N., Laurent, G., Nonclercq, D., Journé, F., Ghanem, G. E., Duvillier, H., Gabius, H.-J., Lechien, J., & Saussez, S. (2013). Pharmacological inhibition of macrophage migration inhibitory factor interferes with the proliferation and invasiveness of squamous carcinoma cells. International journal of oncology, 43(1), 185-193. doi:10.3892/ijo.2013.194451.
El Hajj, P., Journé, F., Wiedig, M., Laïos, I., Salès, F., Galibert, M.-D., Van Kempen, L. C., Spatz, A., Badran, B., Larsimont, D., Awada, A., & Ghanem, G. E. (2013). Tyrosinase-related protein 1 mRNA expression in lymph node metastases predicts overall survival in high-risk melanoma patients. British Journal of Cancer, 108(8), 1641-1647. doi:10.1038/bjc.2013.11552.
Kamagaju, L., Morandini, R., Bizuru, E., Nyetera, P., Nduwayezu, J.-B., Stévigny, C., Ghanem, G. E., & Duez, P. (2013). Tyrosinase modulation by five Rwandese herbal medicines traditionally used for skin treatment. Journal of ethnopharmacology, 146(3), 824-834. doi:10.1016/j.jep.2013.02.01053.
Herraiz, C., Journé, F., Ghanem, G. E., Jimenez-Cervantes Frigo, C., & Garcia-Borron, J. C. (2012). Functional status and relationships of melanocortin 1 receptor signaling to the cAMP and extracellular signal-regulated protein kinases 1 and 2 pathways in human melanoma cells. International journal of biochemistry & cell biology, 44(12), 2244-2252. doi:10.1016/j.biocel.2012.09.00855.
Gembarska, A., Luciani, F., Fedele, C., Russell, E. A., Dewaele, M., Villar, S., Zwolinska, A., Haupt, S., de Lange, J., Yip, D., Goydos, J., Haigh, J. J., Haupt, Y., Larue, L., Jochemsen, A., Shi, H., Moriceau, G., Lo, R. S., Ghanem, G. E., Shackleton, M., Bernal, F., & Marine, J.-C. (2012). MDM4 is a key therapeutic target in cutaneous melanoma. Nature medicine, 18, 1239-1247. doi:10.1038/nm.2863